Circulatory System: Red Blood Cells, White Blood Cells, and Coagulation

Red Blood Cell Characteristics and Development

• Overview and Hematopoiesis Progression:

  • Red blood cells (RBCs), or erythrocytes, originate in the red bone marrow from undifferentiated, pluripotent stem cells.

  • Developmental lineage sequence:

  • Stem cells $\rightarrow$ Undifferentiated / Pluripotent cells $\rightarrow$ Erythroblasts $\rightarrow$ Normoblasts $\rightarrow$ Reticulocytes $\rightarrow$ Mature Erythrocytes.

• Sites of Erythropoiesis Across Life Stages:

  • Embryonic and Fetal Stage:

  • By the 2nd month of intrauterine life, the liver serves as the primary organ producing red blood cells. Bone structures and red bone marrow have not yet formed at this developmental stage. (Fetal heart contraction begins by approximately 6 weeks of gestation).

  • By the 5th month of intrauterine life, the spleen becomes active in producing blood cells alongside initial bone marrow contribution.

  • At Birth:

  • Only minimal blood-producing activity remains in the liver, and virtually no activity remains in the spleen.

  • Adult Stage:

  • RBC production is restricted to the red bone marrow found in specific skeletal locations:

    • Skull

    • Vertebrae

    • Ribs

    • Sternum

    • Pelvis

    • Proximal epiphyses of long bones

• Quantitative Parameters and Dimensions:

  • Erythrocyte Counts:

  • Adult males: Approximately $5{,}500{,}000\,\text{RBCs per cubic millimeter}$ ($5.5 \times 10^6\,\text{mm}^{-3}$).

  • Adult females: Approximately $4{,}500{,}000\,\text{RBCs per cubic millimeter}$ ($4.5 \times 10^6\,\text{mm}^{-3}$).

  • Cellular Dimensions:

  • Shape: Biconcave disc.

  • Diameter: Approximately $7.5\,\mu\text{m}$.

  • Thickness (at the thickest peripheral border): Approximately $2.5\,\mu\text{m}$.

  • Biological reference standard: Knowing the baseline diameter of $7.5\,\mu\text{m}$ allows estimation of other cell sizes (e.g., a monocyte measuring $15.0\,\mu\text{m}$ is calculated as $2 \times 7.5\,\mu\text{m}$).

• Structural Features and Lifespan:

  • Absence of organelles: Mature human RBCs lack a nucleus, mitochondria, and ribosomes.

  • Metabolic and functional consequences:

  • No protein synthesis can occur within mature erythrocytes.

  • RBCs cannot undergo cellular division or self-repair.

  • Adenosine triphosphate (ATP) production depends entirely on anaerobic glycolysis via glycolytic enzymes due to the complete lack of mitochondria.

  • Lifespan: Approximately $120\,\text{days}$, after which senescent cells undergo phagocytic destruction and replacement.

• Primary Functions:

  • Transport oxygen ($O_2$) from pulmonary capillary beds to systemic tissues.

  • Transport carbon dioxide ($CO_2$) from systemic tissues back to the lungs.

Hemoglobin Structure, Variants, and Gas Transport

• Hemoglobin Molecule Architecture:

  • Structural level: Quaternary protein structure (representing the highest level of protein folding and multi-subunit organization).

  • Subunit composition of Adult Hemoglobin ($HbA$):

  • Composed of 4 polypeptide chains: 2 alpha ($\alpha$) chains and 2 beta ($\beta$) chains.

  • Contains 4 non-protein, iron-containing heme groups, with one heme group located at the center of each polypeptide chain.

• Fetal Hemoglobin ($HbF$):

  • Structural difference: Composed of 2 alpha ($\alpha$) chains and 2 gamma ($\gamma$) chains (instead of the beta chains present in adult hemoglobin).

  • Functional advantage: Possesses a significantly higher chemical affinity for oxygen than adult hemoglobin, enabling fetal RBCs to extract oxygen efficiently from maternal circulation even under low partial pressures ($P_{O_2}$).

• Normal Hemoglobin Concentrations:

  • Adult males: $16\,\text{to}\,18\,\text{g/dL}$ ($16\,\text{to}\,18\,\text{g/100\,mL}$).

  • Adult females: $12\,\text{to}\,14\,\text{g/dL}$ ($12\,\text{to}\,14\,\text{g/100\,mL}$).

  • Substantially lower values are diagnostic of anemia.

• Heme Group Chemistry and Binding Dynamics:

  • Ring structure:

  • Features a single iron atom held at the center of each porphyrin ring.

  • Ring structure incorporates nitrogen atoms, which present unique metabolic handling and nitrogenous waste excretion challenges for the body during breakdown.

  • Reversible oxygen binding:

  • The atomic configuration confers an affinity for oxygen that is strong enough to load oxygen in pulmonary capillaries but loose enough to unload oxygen readily in peripheral tissue capillaries under lower oxygen partial pressures.

  • Carbon Monoxide ($CO$) Toxicity:

  • Carbon monoxide binds to the central iron atom of the heme group with an affinity vastly exceeding that of oxygen.

  • $CO$ binding is virtually irreversible, permanently blocking oxygen transport on affected hemoglobin molecules.

  • Cigarette smoking generates carbon monoxide that permanently ties up a distinct percentage of circulating hemoglobin, compromising oxygen delivery and peak athletic performance.

• Erythrocyte Membrane Asymmetry:

  • The cell membrane consists of a phospholipid bilayer exhibiting asymmetry between its inner and outer leaflets.

  • The lipid composition and molecular orientation of the outer plasma membrane layer differ fundamentally from those of the inner cytoplasmic layer.

Comparative Erythrocyte Physiology Across Species

• Mammalian Species:

  • Mammals across vastly different body masses (including humans, blue whales, elephants, rodents, and marsupials) maintain nearly identical erythrocyte diameters (human diameter $\approx 7.5\,\mu\text{m}$).

• Avian Species:

  • Bird erythrocytes are larger than mammalian erythrocytes and retain a functional cell nucleus.

• Reptilian Species:

  • Reptile RBCs (e.g., crocodiles, pythons) are noticeably larger than mammalian RBCs and are nucleated.

• Amphibian Species:

  • Bullfrog (Bufo) RBCs are approximately $1.5 \times$ larger than human RBCs.

  • Salamander (Necturus / Amphiuma) RBCs are gigantic, measuring approximately $5 \times\,\text{to}\,6 \times$ the size of human RBCs.

• Fish Species:

  • Trout (salmonids) possess large, nucleated erythrocytes.

  • Common Goldfish RBCs measure $10\,\mu\text{m}$ in diameter (compared to $7.5\,\mu\text{m}$ in humans).

Regulation of Erythropoiesis and High-Altitude Adaptations

• Renal Feedback Mechanism:

  • Primary sensing organ: Kidneys.

  • Physiological trigger: Hypoxia (decreased oxygen delivery or supply to kidney tissues).

  • Hormonal mediator: Renal cells synthesize and secrete the hormone erythropoietin (EPO).

  • Target tissue and response: EPO travels through systemic circulation to red bone marrow, directly stimulating erythrocyte differentiation and production.

  • Therapeutic applications: Recombinant EPO (e.g., Procrit) is administered to stimulate RBC production in cancer patients undergoing bone marrow-suppressive chemotherapy and in severe alcoholics experiencing impaired hematopoiesis.

  • Pathological risks of artificial EPO elevation / Blood Doping:

  • Exogenous EPO administration (blood doping) excessively increases hematocrit and total blood viscosity.

  • Hyperviscous blood significantly increases resistance to flow, predisposing individuals to lethal intravascular blood clots, myocardial infarction, and stroke.

• High-Altitude Hematological Adaptations:

  • Environmental trigger: Ambient high altitude lowers atmospheric partial pressure of oxygen, triggering chronic renal hypoxia and elevated EPO release.

  • Baseline sea-level hematocrit ($Hct$) values:

  • Males: $45\%\,\text{to}\,47\%$

  • Females: $40\%\,\text{to}\,42\%$

  • Altitude-adapted population comparative data:

  • Himalayan Populations: Demonstrate a mean hematocrit of $50\%$, adapting to high altitude through both increased RBC count and hyper-perfusion of systemic organs.

  • Andean Populations: Demonstrate a mean hematocrit of $54\%$.

  • Regulatory athletic limits: Elite athletic governing bodies (e.g., Tour de France) enforce strict hematocrit cutoffs (disqualifying individuals with hematocrit levels at or exceeding $54\%$) to prevent cheating via EPO doping.

Red Blood Cell Lifecycle and Recycling Pathways

• Turnover Rates:

  • Total circulating lifespan: Approximately $120\,\text{days}$.

  • Destruction and replacement velocity: $2 \times 10^6\,\text{to}\,3 \times 10^6\,\text{RBCs per second}$ ($2\,\text{to}\,3\,\text{million/s}$).

• Step-by-Step Degradation and Recycling Pathway:

  • Step 1: Phagocytosis:

  • Senescent RBCs lose membrane elasticity and undergo phagocytosis by fixed macrophages within the spleen, liver, and red bone marrow.

  • Step 2: Globin Hydrolysis:

  • The protein portion (globin) is broken down into constituent amino acids, which are released into systemic plasma to be reused in protein synthesis.

  • Step 3: Iron ($Fe$) Conservation:

  • Iron is extracted from the heme ring and released into plasma.

  • Iron binds to the transport protein transferrin.

  • Transferrin delivers iron to the liver for storage (as ferritin or hemosiderin) or to red bone marrow for immediate insertion into new hemoglobin chains.

  • Step 4: Non-Iron Heme Processing:

  • The non-iron porphyrin ring of heme is enzymatically converted inside macrophages into the green pigment biliverdin.

  • Biliverdin is reduced into the yellow-orange pigment bilirubin and released into plasma.

  • Bilirubin binds plasma proteins, travels to the liver, and is processed by hepatocytes before being excreted as bile salts into the small intestine.

  • In the lumen of the large intestine, resident bacteria convert bilirubin into urobilinogen.

  • Step 5: Urobilinogen Excretion Routes:

  • Renal Excretory Route: A fraction of urobilinogen is reabsorbed into the bloodstream, cleared by the kidneys, oxidized into urobilin (a yellow pigment), and excreted, giving urine its characteristic yellow color.

  • Fecal Excretory Route: Unabsorbed urobilinogen remaining in the large intestine is converted by colonic bacteria into stercobilin (a brown pigment), which is excreted in feces, giving stool its characteristic brown color.

  • Step 6: Clinical Pathology (Biliary Obstruction):

  • Complete obstruction of the bile duct prevents hepatic bilirubin from entering the intestines.

  • In the absence of intestinal bacterial conversion to stercobilin, feces take on a distinct white, clay-like appearance.

Anemias and White Blood Cell (Leukocyte) Classification

• Etiological Classification of Anemias:

  • Nutritional Anemias:

  • Pernicious Anemia: Caused by Vitamin $B_{12}$ deficiency (frequently secondary to a lack of gastric intrinsic factor).

  • Folic Acid Deficiency: Caused by inadequate dietary intake or absorption of folate.

  • Hypochromic (Iron-Deficiency) Anemia:

  • Represents $90\%$ of all diagnosed anemia cases.

  • Highly prevalent in females due to monthly iron loss during normal menstrual bleeding.

  • Sickle Cell Anemia:

  • Genetic hemoglobinopathy resulting from a single amino acid substitution out of the $287$ amino acids in the globin polypeptide chain.

  • Induces deoxygenated hemoglobin aggregation, distorting erythrocytes into rigid, sickle-like shapes.

  • Hemorrhagic Anemia: Direct result of rapid, substantial blood loss.

  • Renal Anemia: Caused by deficient renal erythropoietin secretion secondary to chronic kidney disease.

  • Aplastic Anemia: Bone marrow destruction leading to marked suppression of RBC production; caused by exposure to ionizing radiation (X-rays), chemotherapy drugs, or toxic chemicals.

• Leukocyte General Characteristics:

  • Normal circulating leukocyte count: $5{,}000\,\text{to}\,10{,}000\,\text{cells per cubic millimeter}$ ($5 \times 10^3\,\text{to}\,10 \times 10^3\,\text{mm}^{-3}$).

  • Leukocytosis: Abnormally elevated total leukocyte count (typical response to bacterial infection).

  • Leukopenia: Abnormally reduced total leukocyte count; caused by viral infections including influenza, measles, mumps, and chickenpox.

• Granulocytes (Contain conspicuous, membrane-bound cytoplasmic granules):

  • Neutrophils:

  • Abundance: $60\%\,\text{to}\,70\%$ of total circulating WBCs (most common leukocyte).

  • Size: $12\,\text{to}\,15\,\mu\text{m}$ in diameter (approx. $1.5 \times$ RBC diameter).

  • Nuclear morphology: Multi-lobed nucleus with 2 to 5 distinct nuclear lobes connected by thin strands (often termed "polys" or polymorphonuclear leukocytes).

  • Immature forms: Banded neutrophils ("bands"), featuring an unsegmented, rod-like nucleus.

  • Female nuclear marker: Neutrophils in females may display an inactive X-chromosome appendage known as a "Barr body" or "drumstick".

  • Function: Active microphagocytes that migrate to acute infection sites to phagocytize invading bacteria.

  • Eosinophils:

  • Abundance: $2\%\,\text{to}\,4\%$ of total circulating WBCs.

  • Size: $12\,\text{to}\,16\,\mu\text{m}$ in diameter.

  • Nuclear morphology: Typically bilobed nucleus.

  • Granule staining: Cytoplasmic granules stain distinctively orange-red with acidic dyes (unique among leukocytes).

  • Function: Phagocytize antigen-antibody complexes; counts rise during allergic conditions (e.g., hay fever) and parasitic infestations (e.g., hookworm, trichinosis).

  • Basophils:

  • Abundance: Less than $1\%$ (approx. $0.5\%$) of total circulating WBCs (rarest leukocyte).

  • Size: $9\,\text{to}\,10\,\mu\text{m}$ in diameter.

  • Nuclear morphology: Bilobed nucleus (frequently obscured by granules).

  • Granule staining: Large, coarse granules that stain intense blue-black with basic dyes.

  • Function: Secrete histamine (promotes inflammation and vasodilation in allergic responses) and heparin (an anticoagulant); play a minor role in blood clotting.

• Agranulocytes (Lack conspicuous cytoplasmic granules under light microscopy):

  • Monocytes:

  • Abundance: $3\%\,\text{to}\,8\%$ of total circulating WBCs.

  • Size: $20\,\text{to}\,25\,\mu\text{m}$ in diameter (the largest circulating blood cell, approx. $3 \times$ RBC diameter).

  • Morphology: Lightly staining, indented nucleus (kidney-bean shaped); abundant grayish-blue cytoplasm.

  • Function: Leave circulation to become mobile macrophages in tissues, phagocytizing pathogens and debris.

  • Lymphocytes:

  • Abundance: $20\%\,\text{to}\,30\%$ of total circulating WBCs (second most abundant leukocyte).

  • Size: Small lymphocytes measure $8\,\text{to}\,10\,\mu\text{m}$ in diameter.

  • Morphology: Large, dark-staining spherical nucleus filling almost the entire cell, surrounded by a thin halo of cytoplasm.

  • Functional classes:

    • B Lymphocytes: Produce and secrete humoral antibodies.

    • T Lymphocytes: Mediate cell-mediated immune responses.

    • Natural Killer (NK) Cells: Cytotoxic lymphocytes that destroy virus-infected and malignant cells.

    • Note: B and T lymphocytes are morphologically indistinguishable under standard light microscopy.

• Leukocyte Lifespans:

  • Granulocytes generally survive for a few hours to a few days.

  • Agranulocytes can survive in tissues for over $100\,\text{days}$.

• Platelets (Thrombocytes):

  • Circulating count: Approximately $250{,}000\,\text{per cubic millimeter}$ ($2.5 \times 10^5\,\text{mm}^{-3}$).

  • Structure: Anucleate membrane-bound cellular fragments derived from megakaryocytes.

Mechanisms of Blood Coagulation and Hemostasis

• Overview of Hemostasis:

  • Blood clotting is driven by two distinct initiation pathways—the extrinsic pathway and the intrinsic pathway—both converging into a single common pathway.

• Extrinsic Clotting Mechanism:

  • Trigger: Initiated by vascular or tissue damage outside the blood vessel (e.g., a skin laceration).

  • Initiating agent: Traumatized tissues release Tissue Thromboplastin (Factor III), a protein not normally present within circulating blood.

  • Cascade: Factor III complexes with calcium ions ($Ca^{2+}$) and Factor VII to rapidly activate Factor X, quickly initiating the common pathway.

• Intrinsic Clotting Mechanism:

  • Trigger: Initiated by internal vascular wall damage exposing subendothelial connective tissue (collagen) to blood components.

  • Sequential Stage Execution:

  1. Platelet Adhesion: Contact with exposed collagen triggers platelets to adhere to the damaged surface.

  2. Platelet Release Reaction: Adherent platelets release adenosine diphosphate (ADP).

  3. Platelet Aggregation: ADP causes neighboring platelets to become sticky and aggregate, building a physical platelet plug.

  4. Limiting Aggregation: Adjacent undamaged endothelial cells release prostacyclin and nitric oxide ($NO$), which actively inhibit platelet aggregation outside the injury site.

  5. Factor cascade: Intrinsic plasma factors (Factors XII, XI, IX, VIII) sequentially activate to trigger Factor X.

• Key Clotting Factors and Designations:

  • Factor I: Fibrinogen (a soluble plasma protein).

  • Factor II: Prothrombin (an inactive plasma zymogen; evaluated clinically via "Prothrombin Time" [PT] testing).

  • Factor III: Tissue Thromboplastin.

  • Factor IV: Calcium ions ($Ca^{2+}$; essential ionic cofactor required in nearly every stage of coagulation).

  • Factor VIII: Antihemophilic Factor (deficient in classic Hemophilia A).

  • Factor IX: Christmas Factor (named after the patient Stephen Christmas; deficient in Hemophilia B).

  • Factor X: Stuart Factor / Stuart-Prower Factor (the initial enzyme of the common pathway).

• The Common Pathway and Fibrin Mesh Formation:

  1. Activation of Factor X by either the intrinsic or extrinsic pathway initiates the common pathway.

  2. Activated Factor X complexes with Factor V, Platelet Factor 3, and calcium ions ($Ca^{2+}$) to convert Prothrombin (Factor II) into the active enzyme Thrombin.

  3. Thrombin cleaves soluble Fibrinogen (Factor I) by removing peptide fragments.

  4. Cleaved fibrinogen turns into insoluble Fibrin monomers, which rapidly polymerize into long fibrin threads.

  5. Fibrin threads form a meshwork that entangles blood cells and platelets to seal the vascular defect.

  6. Clot Retraction: The fibrin mesh contracts, pulling the damaged vessel margins together and expressing serum (plasma completely depleted of fibrinogen and clotting proteins).

Coagulation Disorders, Anticoagulants, and Fibrinolysis

• Coagulation Disorders:

  • Hemophilia A (Classic Hemophilia): Sex-linked genetic deficiency of Factor VIII; affects approximately $15{,}000\,\text{to}\,20{,}000$ individuals in the United States.

  • Hemophilia B (Christmas Disease): Sex-linked genetic deficiency of Factor IX.

  • Thrombus: An intravascular blood clot attached to the interior vessel wall.

  • Embolus: A thrombus fragment that detaches and travels through the circulatory system until it occludes a smaller downstream vessel (e.g., pulmonary embolus).

  • Thalassemia: Hereditary anemia prevalent in Mediterranean populations (e.g., individuals of Greek descent), structurally analogous to sickle cell anemia.

• Pharmacological Anticoagulants and Fibrinolytic Agents:

  • Heparin: Antithrombin anticoagulant administered parenterally in hospital settings to prevent acute clot extension.

  • Coumadin (Warfarin) / Dicumarol: Oral anticoagulants that inhibit vitamin K-dependent clotting factor synthesis; side effects include extensive micro-vessel bleeding and subcutaneous bruising.

  • Aspirin: Inhibits prostaglandin synthesis, reducing platelet stickiness and aggregation; prescribed daily following biological (animal-derived) heart valve replacements.

  • EDTA (Ethylenediaminetetraacetic Acid): A synthetic chelating agent that binds free calcium ions ($Ca^{2+}$), preventing coagulation in stored blood products.

  • Streptokinase & TPA (Tissue Plasminogen Activator): Thrombolytic agents administered intravenously to actively dissolve coronary artery blood clots during an acute myocardial infarction.

  • Snake Venom Applications: Derivatives of venom from the South American pit viper, when combined with hydrogels, create materials that rapidly stop wound bleeding even in patients taking full-dose anticoagulants.

• Fibrinolysis (Clot Dissolution Pathway):

  • Inactive plasminogen circulates constantly in plasma.

  • Tissue Plasminogen Activator (TPA) cleaves plasminogen into the active enzyme plasmin (also known as fibrinolysin).

  • Plasmin slowly degrades insoluble fibrin threads over days as damaged vascular endothelium repairs itself.

Royal Hemophilia History and ABO/Rh Blood Grouping

• Historical Impact of Hemophilia A:

  • Queen Victoria of England was a spontaneous carrier of Hemophilia A.

  • Her son Prince Leopold suffered from hemophilia; her daughters Alice and Beatrice carried the gene into German, Spanish, and Russian royal dynasties.

  • Tsarina Alexandra of Russia (Victoria's granddaughter) carried the allele and passed it to her son, Tsarevich Alexei.

  • The Tsarina relied heavily on the mystic Rasputin, who used hypnosis to reduce pain and slow hemorrhaging in Alexei.

  • Rasputin's resulting political influence over the tsarist court destabilized the imperial government, contributing to the Russian Revolution of 1917.

• ABO Blood Grouping System:

  • Discovered by Karl Landsteiner in 1901.

  • Determined by permanent membrane-bound antigens on RBCs and circulating antibodies in plasma.

  • System Rules:

  • Type A Blood: Possesses Antigen A on RBCs; contains Antibody B (anti-B) in plasma.

  • Type B Blood: Possesses Antigen B on RBCs; contains Antibody A (anti-A) in plasma.

  • Type AB Blood: Possesses both Antigen A and Antigen B on RBCs; contains neither Antibody A nor Antibody B in plasma.

  • Type O Blood: Possesses neither Antigen A nor Antigen B on RBCs; contains both Antibody A and Antibody B in plasma.

• Agglutination Reactions:

  • Occurs when a specific RBC surface antigen mixes with its corresponding plasma antibody (e.g., Antigen A encountering Antibody A), causing severe RBC cross-linking and clumping (agglutination).

• ABO & Rh Population Distributions in the United States:

  • Distribution hierarchy by frequency in the general US population:

  1. $\text{O}^+$ (most common blood type overall)

  2. $\text{A}^+$

  3. $\text{B}^+$

  4. $\text{O}^-$

  5. $\text{A}^-$

  6. $\text{AB}^+$

  7. $\text{B}^-$

  8. $\text{AB}^-$ (rarest blood type; present in only $0.7\%$ of the population).

• Transfusion Dynamics:

  • Universal Donor: Type $\text{O}^-$ (O negative) blood. Lacks A, B, and Rh membrane antigens, allowing safe emergency transfusion prior to lab cross-matching.

  • Universal Recipient: Type $\text{AB}^+$ (AB positive) blood. Lacks anti-A, anti-B, and anti-Rh antibodies in plasma, allowing receipt of packed RBCs of any blood type.

• Rh Factor and Demographic Variations:

  • The Rh Factor is an additional erythrocyte surface antigen; individuals expressing it are $\text{Rh}^+$ ($85\%$ of the US population), while those lacking it are $\text{Rh}^-$ ($15\%$).

  • In specific populations (e.g., Chinese Americans, Filipino Americans, Native Hawaiians, Japanese Americans, Korean Americans), nearly $100\%$ of individuals are $\text{Rh}^+$.

  • Regional/ethnic allele frequency patterns:

  • The $\text{B}$ allele exhibits elevated frequencies in Indian and Asian populations.

  • The $\text{A}$ allele exhibits elevated frequencies in Australian and Northern European populations.

  • The $\text{O}$ allele is present in up to $90\%$ of Indigenous and Hispanic populations in South America, Central America, Mexico, and the American Southwest.